Explore the intricate world of the biotech industry, delving deep into current trends and challenges through our collection of in-depth analysis articles.| Labiotech.eu
Novartis has been on a shopping spree of late. Find out about the pharma giant's latest deals of 2025. The post Deal after deal: Novartis spends billions in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu wi...| Labiotech.eu
With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents. The post PCSK9’s second act: From antibodies to gene editing appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech...| Labiotech.eu
Check out some of the top biotech companies with headquarters in South San Francisco, also known as the Birthplace of Biotechnology. The post Seven of the top biotech companies to know about in South San Francisco appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear c...| Labiotech.eu
Discover recent Tourette’s syndrome research, highlighting emerging therapies and biotech advances in this neurological disorder. The post Five latest advancements in Tourette’s syndrome research appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given...| Labiotech.eu
As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden. The post NLS Days: How do things look for biotech in Sweden? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG an...| Labiotech.eu
In today's episode, we welcome Clarke Futch, Chairman and CEO of HealthCare Royalty Partners, or HCRx, with a thirty year track record in biopharma investing. The post Biotech royalty deals on the rise and here to stay appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and cl...| Labiotech.eu
As the biotech industry in Luxembourg gradually grows, let us take a look at five biotech companies that are flourishing in the field. The post Biotech in Luxembourg: five companies that have made their name appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit ...| Labiotech.eu
Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for peptides? The post The advent of AI for peptide design: An emerging field appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given ...| Labiotech.eu
The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval. The post Prader Willi syndrome: five much-anticipated therapies poised for approval appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, pr...| Labiotech.eu
Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so special. The post Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangle appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and cle...| Labiotech.eu
We were on the ground in Barcelona speaking to biotech companies, university technology transfer offices, and top pharma firms about their experience at BIOSPAIN and their progress towards securing partnerships. The post Practical partnering at BIOSPAIN: on the ground with biotech innovators ready to take the next step appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s...| Labiotech.eu
In this week's podcast we talked with Kevin Eisenfrats, CEO of Contraline, about contraception, male contraception. The post Contraline’s ADAM in the clinic: towards a new era of male contraception? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is give...| Labiotech.eu
Contrary to popular belief, Francis Mojica was the first person to discover the CRISPR mechanism and give it its name. He told me how the discovery came about, discussed the wide potential of the gene editing tool and shared his favorite CRISPR application.| Labiotech.eu
Discover the best in biotech: companies, influential individuals, locations, and more! Explore our curated lists of excellence in the biotech world.| Labiotech.eu
The German biotech ecosystem is well established despite the challenges it is facing. Discover fourteen key Germany-based biotech companies.| Labiotech.eu
As the release of a CRL declining Lykos' therapy generates a strong reaction from MAPS, delve into what this new transparency could change.| Labiotech.eu
Get the latest news on the applications of Artificial Intelligence (AI) and machine learning in drug discovery, healthcare, agriculture, and more.| Labiotech.eu
The past year saw pipeline cuts and downsizing plans strike the biotech industry. Does the biotech job market seem to be looking up this year?| Labiotech.eu
As the biotech industry flourishes, drug developers need to interact increasingly with patient organizations, especially in the rare disease space.| Labiotech.eu
Unlock exclusive career opportunities in biotech and biopharma with our curated list of top life sciences job boards.| Labiotech.eu
Biotech startups are a high-risk venture. Experts explain what the most common reasons for failure are and what can be done to avoid them.| Labiotech.eu
Funding a biotech startup can be challenging. Delve into our guide to navigate this complicated investment landscape.| Labiotech.eu
Mission statement, purpose and vision are essential to the success of a biotech. Delve into the stategies to build on company culture.| Labiotech.eu
By Varvara Melikhova, founder and CEO of Unison Innovations Strategic partnerships are a better way to build a product’s capabilities than outright acquisitions. While the M&A path is set out for the most mature successful startups, early-stage partnerships can enhance a product’s market value and provide access to Big Pharma expertise and infrastructure, which significantly […]| Labiotech.eu
The last month has seen several big investments in European neuromodulation and neurostimulation companies, which aim to treat neurological conditions by zapping nerve cells. What's the reason for this funding peak?| Labiotech.eu
Since the Hormone Replacement Therapy market was destroyed almost overnight in 2002, there has been a lot of caution about investing in companies with a focus on women’s health. Mary Kerr, CEO of KaNDy Therapeutics and NeRRe Therapeutics, knows this only too well, but has not let it deter her in her quest to bring a treatment for symptoms of the menopause to the market.| Labiotech.eu
Many biotech entrepreneurs dread the possibility of investors taking control in a situation that resembles a hostile takeover. But it needn't be that way.| Labiotech.eu
Building a biotech startup can be a daunting task and often founders rely on incubators - but how to choose the right one?| Labiotech.eu
Sabine Dandiguian, Managing Partner at the life sciences VC firm Jeito Capital, shares her experience building a thriving company culture.| Labiotech.eu
What's my business model? Who do I partner with? How do I scale up? These are typical strategic questions a young biotech will regularly face.| Labiotech.eu
Explore our articles offering advice and consulting on various aspects of the biotech industry, from strategic planning to market analysis and partnerships.| Labiotech.eu
To honor International Women's Day, we asked female biotech leaders for their tips on how to encourage women in the life sciences industry.| Labiotech.eu
Get the latest biotech news for Europe, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Hiring is a big challenge in biotech; life sciences recruitment experts share their strategies for attracting and retaining talent in the biotech industry.| Labiotech.eu
As new measures are being developed to spur quicker and efficient diagnoses, here are six molecular diagnostics companies to look out for.| Labiotech.eu
Here is a list of 14 biotech podcasts to keep you up to date with the latest advances in the biotechnology industry.| Labiotech.eu
Here’s a list of the 15 public European biotech companies that are worth more than a billion euros in 2022.| Labiotech.eu
To commemorate Lupus Awareness Month in May, here are five advancements in lupus research over the past year.| Labiotech.eu
As we celebrate International Women’s Day, here are 5 women who are leading the way in research and innovation in the biotech industry!| Labiotech.eu
Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer.| Labiotech.eu
The companies Candid Therapeutics, ArsenalBio, and eGenesis bagged the biggest private biotech investments in September 2024.| Labiotech.eu
The companies Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics bagged the biggest private biotech investments in October 2024.| Labiotech.eu
The companies Uniquity Bio, AltruBio, and BridgeBio Oncology Therapeutics bagged the biggest private biotech investments in May 2024.| Labiotech.eu
The companies Formation Bio, Isotopen Technologien München, and Marea Therapeutics bagged the biggest private biotech investments in June 2024.| Labiotech.eu
The companies Xaira Therapeutics, Metsera, and Obsidian Therapeutics bagged the biggest private biotech investments in April 2024.| Labiotech.eu
Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped capital.| Labiotech.eu
Abivax, MapLight Therapeutics, Everest Medicines, and Soleno Therapeutics bagged the biggest biotech funding rounds overall in July 2025.| Labiotech.eu
New narcolepsy treatments are being tested in the clinic, and recently, some of them have made promising strides. How far along are they?| Labiotech.eu
NATO Innovation Fund backs Portal Biotech in its first biotech move. What does this signal for strategic investment in healthcare innovation?| Labiotech.eu
A spate of royalty deals are changing the way certain biotechs press ahead, as seen with Cytokinetics’ agreement with Royalty Pharma.| Labiotech.eu
Get the latest biotech news for Career, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Discover expert advice from recruiters on crafting a standout biotech resume that grabs employers' attention and lands you interviews.| Labiotech.eu
Check out five important biotechnology careers that are currently in high demand, and likely still will be in the coming years.| Labiotech.eu
Building a career in biotech can be a daunting task without the right skills. Delve into the strategies to improve and leverage them.| Labiotech.eu
Alan Levy shares his experience on how to make the relationship between the board and the CEO of a life sciences company work.| Labiotech.eu
Find the top upcoming international biotech conferences, events, seminars, webinars, and workshops for 2024!| Labiotech.eu
Here is a list of ten recruiters in the biotech space, nominated by our readers, who are making strides in the life science sector.| Labiotech.eu
The companies Metsera, Alentis Therapeutics, and Adcendo bagged the biggest private biotech investments in November 2024.| Labiotech.eu
The companies Cardurion Pharmaceuticals, Beacon Therapeutics, and Third Arc Bio bagged the biggest private biotech investments in July 2024.| Labiotech.eu
The companies Borealis Biosciences, Outpace Bio, and Halda Therapeutics bagged the biggest private biotech investments in August 2024.| Labiotech.eu
The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January 2025.| Labiotech.eu
Get the latest biotech news for USA, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Get the latest biotech news for United Kingdom, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Get the latest biotech news for China, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Those are our privacy policies, showing you how we respect your privacy and your data, so we all live in a happy and non-spammy world :)| Labiotech.eu
The month of December 2024 saw a variety of biotech deals take place to advance therapies across different stages in development.| Labiotech.eu
The companies Nuvig Therapeutics, Ottimo Pharma, and Angitia Biopharmaceuticals bagged the biggest private biotech investments in December 2024.| Labiotech.eu
GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.| Labiotech.eu
The emerging spatial transcriptomics field is letting researchers map out gene expression in tumor and brain samples. How could this change the way we treat disease?| Labiotech.eu
In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.| Labiotech.eu
Take a look at six multiple sclerosis companies trying to make a difference to patients by advancing new treatments for the CNS disease.| Labiotech.eu
Here are eight nanotechnology companies that are widening the scope in medicine, that you should know about.| Labiotech.eu
Find out more about six biomimicry companies harnessing nature’s wisdom to create drug candidates for the benefit of human health.| Labiotech.eu
Stay informed about the latest clinical trial news, inlcuding the outcomes of ongoing clinical trials, new innovative trial methodologies, and more!| Labiotech.eu
Eisai and Biogen have announced that the FDA has approved LEQEMBI 100 mg/mL injection for intravenous use for treating Alzheimer's disease.| Labiotech.eu
Get the latest news related to Alzheimer's, including the latest research, partnerships, and technology advancements of alzheimer's biotech companies.| Labiotech.eu
Learn more about Biogen's strategic realignment from Aduhelm's controversy to Leqembi's promise in Alzheimer's treatment.| Labiotech.eu
As we observe Alzheimer's & Brain Awareness Month in June, here are six recent advancements that could transform Alzheimer's research.| Labiotech.eu
Get the latest biotech news for Immunotherapy, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Get the latest biotech news for Cancer, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
mRNA vaccines have been used for cancer therapies as well as for protection from infectious diseases, particularly for COVID-19.| Labiotech.eu
Discover promising advancements in oncology clinical trials presented by experts and biotechs from around the globe at ASCO 2024.| Labiotech.eu
Get the latest biotech news for GPCR, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Get the latest biotech news for Antibodies, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Take a closer look at how the obesity drug market is currently soaring after the success of new weight loss drugs like Wegovy.| Labiotech.eu
GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs.| Labiotech.eu
Get the latest biotech news for investment, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
Get the latest biotech news for Funding, including the latest research, partnerships, regulations, and technology advancements.| Labiotech.eu
On its way to tackle cancer therapy resistance with its monoclonal antibody visugromab, CataLym completes a $150 million series D round.| Labiotech.eu
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.| Labiotech.eu
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio's spinout.| Labiotech.eu
The companies Mirador Therapeutics, Alumis, and Sionna Therapeutics bagged the biggest private biotech investments in March 2024.| Labiotech.eu
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.| Labiotech.eu
Explore 10 gene therapy companies operating within the biotech industry, as each one hopes to develop their own novel candidates.| Labiotech.eu
Discover our top biotech job tips, as we list five things you could do to increase your chances of securing your dream job in the industry.| Labiotech.eu
The past few years have been challenging for the industry but 2024 might be the year marking the biotech recovery.| Labiotech.eu
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.| Labiotech.eu
